Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesAmortization of GoodwillAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Maravai Lifesciences Holdings (MRVI) Net Cash Flow (2020 - 2025)

Maravai Lifesciences Holdings (MRVI) has 6 years of Net Cash Flow data on record, last reported at -$26.7 million in Q4 2025.

  • For Q4 2025, Net Cash Flow rose 89.56% year-over-year to -$26.7 million; the TTM value through Dec 2025 reached -$105.5 million, up 58.24%, while the annual FY2025 figure was -$105.5 million, 58.24% up from the prior year.
  • Net Cash Flow reached -$26.7 million in Q4 2025 per MRVI's latest filing, down from -$26.3 million in the prior quarter.
  • Across five years, Net Cash Flow topped out at $172.6 million in Q3 2021 and bottomed at -$255.8 million in Q4 2024.
  • Average Net Cash Flow over 5 years is -$958700.0, with a median of -$2.2 million recorded in 2023.
  • Peak YoY movement for Net Cash Flow: soared 1559.86% in 2021, then plummeted 5408.46% in 2024.
  • A 5-year view of Net Cash Flow shows it stood at $3.5 million in 2021, then soared by 318.93% to $14.7 million in 2022, then tumbled by 131.6% to -$4.6 million in 2023, then tumbled by 5408.46% to -$255.8 million in 2024, then soared by 89.56% to -$26.7 million in 2025.
  • Per Business Quant database, its latest 3 readings for Net Cash Flow were -$26.7 million in Q4 2025, -$26.3 million in Q3 2025, and -$15.0 million in Q2 2025.